[Skip to Navigation]
December 1976

Acute Granulocytic Leukemia: Treatment of the Disease

Author Affiliations

From the Unité de Chimiothérapie, Institut de Recherches sur les Leucémies et les Maladies du Sang, Hôpital Saint-Louis, Paris.

Arch Intern Med. 1976;136(12):1389-1395. doi:10.1001/archinte.1976.03630120041014

All authors contrast the poor prognosis of acute granulocytic leukemias (AGLs) with the progress achieved in acute lymphocytic leukemias (ALLs). However, many advances have already been made in the treatment of this disease: the median survival remains poor with present chemotherapy, but survival has been shown to be directly related to the attainment of a complete remission (CR). The indications for such intensive treatment must be individualized according to the age of the patient and the morphological findings of the leukemia.

Cytological classification of AGLs is difficult. The cytology of acute promyelocytic and acute monoblastic leukemias (APLs and AMoLs) is now well characterized, but the term acute myeloblastic leukemia (AML) still includes various cytological variants.

We shall deal first with the treatment of AML with an overt maturation arrest (high rate of poorly differentiated cells); then we shall consider the specific problems raised by APL and AMoL and the difficulties

Add or change institution